Market Intelligence, Clinical Progress, and High-Purity Reagents for Psoriasis and Inflammatory Disease Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-36 Gamma drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-36 Gamma (IL36G) Active Truncated / Full-Length Protein High purity (>95%), Endotoxin Controlled (<1 EU/μg). Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View IL36G Products |
| Gene Delivery | IL-36 Gamma (IL36G) Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and functional expression assays. |
View IL36G Products |
| Benchmark Ab | Anti-IL-36 Gamma Recombinant Antibody (including Spesolimab sequence-based control) Recombinant positive control antibody for benchmark binding and neutralization assays. |
View IL36G Products |
| Validator | IL-36 Gamma (IL36G) siRNA Set Target-specific knockdown verification in primary keratinocytes or cell lines. |
View IL36G Products |
| Related Target A | IL-36 Receptor (IL36R / IL-1RL2) The functional receptor required for IL-36 ligand-mediated signaling and competitive binding assays. |
View IL36R Products |
| Related Target B | IL-1RAcP (IL1RAP) Co-receptor recruited by the IL-36/IL-36R complex to initiate downstream NF-κB inflammatory signaling. |
View IL1RAP Products |
| Related Target C | IL-36 Alpha (IL36A) Synergistic IL-36 family agonist; crucial for selectivity profiling and multi-ligand blockade validation. |
View IL36A Products |
| Related Target D | IL-36 Beta (IL36B) Synergistic IL-36 family agonist; essential for assessing broad anti-inflammatory therapeutic scope. |
View IL36B Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Distinguishing active (cleaved) vs. inactive (full-length) IL-36G | Precisely engineered active truncated (e.g., Ala18-Asp169) and full-length proteins, sequence verified by mass spectrometry. |
| Species cross-reactivity (Human/Cyno/Mouse) profiling | Highly purified recombinant Human, Cynomolgus, and Mouse IL-36G orthologs with guaranteed low endotoxin levels. |
| Lack of reliable positive controls for neutralization | Recombinant benchmark antibodies matching clinical-stage reference sequences (e.g., Spesolimab biosimilar). |
| Off-target screening against other IL-1 family members | Complete panel of recombinant IL-1 family proteins (IL-1a, IL-1b, IL-36a, IL-36b, IL-36Ra, IL-38) to verify target specificity. |
Live IL-36 Gamma R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the IL-36 pathway is expanding rapidly, driven by clinical successes in severe inflammatory dermatoses. While first-generation therapies like Spesolimab (Spevigo) target the IL-36 Receptor (IL-36R) to achieve broad inhibition, next-generation drug discovery is shifting focus toward ligand-specific targeting. Specifically, targeting IL-36 Gamma (IL-36G) offers a highly localized therapeutic window, minimizing systemic immunosuppression by sparing other homeostatic pathways.
IL-36G is highly upregulated in epithelial barriers, particularly in the skin and lungs, making it a prime driver of Generalized Pustular Psoriasis (GPP), plaque psoriasis, and chronic obstructive pulmonary disease (COPD). Current drug pipelines are exploring monoclonal antibodies, bispecific antibodies (e.g., IL-36G/IL-23 dual blockers), and small-molecule inhibitors targeting the proteases (such as Cathepsin S) responsible for cleaving and activating IL-36G. Beyond GPP, indications such as Inflammatory Bowel Disease (IBD), atopic dermatitis, and asthma are gaining traction in early-stage studies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (Anti-IL-36G) | Boehringer Ingelheim, AnaptysBio, Incyte | Generalized Pustular Psoriasis (GPP), Plaque Psoriasis, IBD | High-affinity binding assays requiring sequence-verified, active truncated IL-36G proteins. |
| Bispecific Antibodies (e.g., IL-17 / IL-36G) | Pharma/Biotech early-stage pipelines | Severe Psoriasis, Psoriatic Arthritis | Simultaneous binding validation using highly stable, native-glycosylated IL-36G and partner antigens. |
| Protease Inhibitors (Cathepsin S / Elastase) | Various Small Molecule Developers | COPD, Asthma, Skin Inflammation | Cleavage inhibition assays requiring full-length (inactive) IL-36G as a physiological substrate. |
Molecular Differentiation & Assay Strategy
To develop a best-in-class IL-36G-directed therapy, careful molecular differentiation is required across several dimensions:
1. Affinity & Cleavage Specificity
- Need: IL-36G is secreted as an inactive full-length precursor and must be cleaved by proteases (e.g., Cathepsin S, neutrophil elastase) to its active truncated form (Ala18-Asp169). Antibodies must preferentially bind the active form with pM affinity to neutralize high local concentrations of activated cytokine. Binding to the full-length precursor is important for PK/PD prediction.
- Assay: SPR/BLI using active truncated IL-36G vs. full-length IL-36G; cleavage inhibition assay with Cathepsin S and candidate compounds.
2. Receptor Blocking Mechanism
- Need: Antibodies must block the interaction between IL-36G and IL-36R (IL-1RL2) and prevent co-receptor IL-1RAcP recruitment.
- Assay: Competitive ELISA/HTRF with IL-36R capture; cell-based NF-κB reporter assay using HEK293 cells expressing IL-36R and IL-1RAcP, measuring IC50.
3. Cross-Species Reactivity
- Need: For preclinical toxicology and efficacy, cross-reactivity to cynomolgus monkey and mouse IL-36G is required.
- Assay: Ortholog binding panel using recombinant Human/Cyno/Mouse IL-36G in ELISA and SPR.
4. Genetic Variant Awareness
- Note: The reported SNP rs6707930 (UniProt VAR_024505) corresponds to a coding variation in IL36G. While its functional impact remains under investigation, assay development should consider using sequence-verified proteins that include or exclude this variant to ensure reagent consistency.
5. TarMart Support for Assay Development
TarMart provides all critical reagents for these assays: active truncated IL-36G (Ala18-Asp169, HEK293-expressed), full-length IL-36G, benchmark anti-IL-36G antibodies (including Spesolimab sequence), and recombinant Cathepsin S (CTSS) for cleavage studies. Additionally, high-quality IL-36R and IL-1RAcP proteins enable complete receptor complex reconstitution.